[Evaluation of efficacy and tolerance of an antiasthmatic preparation--Ditec, consisting of low doses of disodium cromoglycate and fenoterol].
The efficacy, tolerance and, in addition, the effect of the antiasthmatic drug-Ditec, consisting of low doses disodium cromoglycate (DSCG) and fenoterol on bronchial hyperreactivity (BHR) were evaluated. The studies were carried out on a group of 22 mild asthma patients aged from 10 to 20 years. The patients took DSCG during the first four weeks and then were treated with Ditec, 4 x 2 puffs, for next four weeks. The following parameters were evaluated: symptom score, beta 2-agonist "taken on demand" consumption, spirometry, morning and evening PEF, and possible adverse effects. Decreases in the symptom score, beta 2-agonist consumption (mainly in Ditec period) and increase in PEF during the study were noted. The low doses of DSCG contained in Ditec were as effective as the 80 mg of this drug given previously. No statistically significant decrease in BHR after DSCG treatment was observed. At the end of the Ditec therapy, BHR to histamine markedly diminished. Because the last doses of Ditec were taken 2 hours before the bronchial provocation test with histamine, the increase in tolerance of histamine, mentioned above, was probably only due to the so-called acute effect of beta 2-agonist on BHR. Ditec seems to be a valuable antiasthmatic drug, especially for children and young persons. Unfortunately, our studies did not answer the additional question whether regular treatment with Ditec changes BHR.